GeneDx Holdings Corp. (NASDAQ:WGS) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET
Company Participants
Sabrina Dunbar – Investor Relations
Katherine Stueland – President and Chief Executive Officer
Kevin Feeley – Chief Financial Officer
Conference Call Participants
Daniel Brennan – TD Cowen
William Bonello – Craig Hallum Capital Group
Mark Massaro – BTIG
Matthew Sykes – Goldman Sachs Group, Inc.
Brandon Couillard – Wells Fargo Securities
Matthew Stanton – Jefferies
Operator
Thank you for standing by, and welcome to the GeneDx Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode and after the speaker’s presentation we will have a question-and-answer session Keep in mind that this call is being recorded. [Operator Instructions].
I would now like to turn the call over to Sabrina Dunbar, Investor Relations. Please go ahead.
Sabrina Dunbar
Thank you, operator, and thank you to everyone for joining us today. On the call, we have Katherine Stueland, President and Chief Executive Officer; and Kevin Feeley, Chief Financial Officer.
Earlier today, GeneDx released financial results for the third quarter ended September 30, 2024. Before we begin, please take note of our cautionary statement. We may make forward-looking statements on today’s call, including about our business plans, guidance and outlook. Forward-looking statements inherently involve risks and uncertainties and only reflect our view as of today, October 29, and we are under no obligation to update. When discussing our results, we refer to non-GAAP measures, which exclude certain items from reported results.
Please refer to our third quarter 2024 earnings release and slides available at ir.genedx.com for definitions and reconciliations of non-GAAP measures and additional information regarding our results. Including a discussion of factors that could cause actual results to materially differ from forward-looking statements.
And with that, I’ll turn the call
Read the full article here
